Two Lilly products, two verbs
Foundayo (orforglipron) is swallowed daily. No food or water timing restrictions. Zepbound (tirzepatide) is injected. On the Medicare GLP-1 Bridge, only the KwikPen presentation is in the demonstration.
Saying 'I want the Lilly one' is how the wrong NDC gets written.
Bridge copay versus Bridge eligibility of the device
Approved Bridge is $50 for either listed product. Zepbound that is not KwikPen is not a listed product. Foundayo has no equivalent device trap.
The $50 still does not count toward TrOOP. Extra Help still does not apply. A 2026 Part D GLP-1 still generally blocks the demonstration.
Cash shelves
Foundayo lowest-dose cash via LillyDirect is often about $149. Zepbound cash is a different LillyDirect list — confirm the presentation you will actually inject. Do not paste the Foundayo number onto a pen.
Commercial-plus-card ~$25 is possible for commercial members when the plan covers that NDC. Government coverage excludes the card.
Indication still overrides brand loyalty
Type 2 diabetes, moderate-to-severe OSA, or MASH on the prescription: Part D rules first, not Bridge, even if the family is attached to a Lilly logo.
Fit questions for the visit
Can the person inject. Can they remember a weekly pen. Do they need an oral that ignores breakfast. Will the pharmacy stock KwikPen for Bridge. Those are checklist lines, not advertisements.
Questions
Are Foundayo and Zepbound the same drug?
If I cannot get KwikPen, should I use Foundayo on the same PA?
Does LillyDirect equal Bridge?
Which is cheaper on cash?
Not sure this applies to you?
Answer a few questions and see your own numbers.
Free to see which path is likely cheapest for your coverage.
Check my options